Immunotherapy (e.g., Pembrolizumab, Nivolumab)
Treatment used for 1 condition
Total Trials
300
Total Participants
15K
Avg Effectiveness
65%
Avg Safety Score
45%
Conditions Treated
Click on a condition to view detailed treatment information and clinical trial data.